Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entera Bio Ltd.ENTX · Entity 5464 | Director | August 07, 2026 | August 07, 2026 |
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | May 14, 2026 | May 19, 2026 |
| PFIZER INCPFE · Entity 2863 | Group President | February 25, 2015 | February 27, 2015 |
| PRECIGEN, INC.XON · Entity 4356 | President | September 22, 2016 | September 26, 2016 |
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director | September 25, 2026 | September 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entera Bio Ltd.
Report date August 07, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative | Direct | 65,014 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 25,014 · Balance 65,014 F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07 | Direct | 50,000 |
Reported balance
After 2026-08-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-07 · Grant · Acquired 50,000 · Balance 50,000 F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07 | Direct | 43,014 |
Reported balance
After 2026-08-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-07 · Grant · Acquired 43,014 · Balance 43,014 F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).
Harmony Biosciences Holdings, Inc.
Report date May 14, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14 | Direct | 21,231 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 21,231 · Balance 21,231 F1: The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026.
PFIZER INC
Report date February 25, 2015 · Filed February 27, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 308,254 |
Ending reported balance
After 2015-02-25 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2015-02-25 · Exercise / conversion · Acquired 83,333 · Balance 354,531 F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Row 2 · 2015-02-25 · Grant · Acquired 17,893 · Balance 372,424 F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 3 · 2015-02-25 · Tax withholding · Disposed 6,474 · Balance 365,950 F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 4 · 2015-02-25 · Tax withholding · Disposed 24,856 · Balance 341,094 F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Row 5 · 2015-02-25 · Tax withholding · Disposed 32,840 · Balance 308,254 F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $17.69 · Expires 2015-02-25 | Direct | 0 |
Reported balance
After 2015-02-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2015-02-25 · Exercise / conversion · Disposed 83,333 · Balance 0 |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $34.59 · Expires 2020-02-26 | Direct | 144,928 |
Reported balance
After 2015-02-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2015-02-26 · Grant · Acquired 144,928 · Balance 144,928 F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $34.59 · Expires 2022-02-26 | Direct | 120,805 |
Reported balance
After 2015-02-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2015-02-26 · Grant · Acquired 120,805 · Balance 120,805 F9: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy children | 1,587 |
Reported balance
Holding disclosure · report date 2015-02-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,587 F7: The reporting person disclaims beneficial ownership of shares held by members of his family. |
| Common StockSEC Table I · non-derivative | IndirectBy Rule 16b-3 Plan | 1,161 |
Reported balance
Holding disclosure · report date 2015-02-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 1,161 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).
F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).
F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
F7: The reporting person disclaims beneficial ownership of shares held by members of his family.
F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
F9: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.
PRECIGEN, INC.
Report date September 22, 2016 · Filed September 26, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.94 · Expires 2026-05-31 | Direct | 1,000,000 |
Reported balance
After 2016-09-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-22 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: This award represents the Issuer's remaining obligation to grant the reporting person option awards for 2,000,000 shares. A Form 4 dated June 3, 2016 reported that the reporting person previously received an option for 2,000,000 shares. That Form 4 has subsequently been amended to reflect that the initial grant was only effective with respect to 1,000,000 shares. This Form 4 reports that the reporting person has now received an option for the remaining 1,000,000 shares. F2: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This award represents the Issuer's remaining obligation to grant the reporting person option awards for 2,000,000 shares. A Form 4 dated June 3, 2016 reported that the reporting person previously received an option for 2,000,000 shares. That Form 4 has subsequently been amended to reflect that the initial grant was only effective with respect to 1,000,000 shares. This Form 4 reports that the reporting person has now received an option for the remaining 1,000,000 shares.
F2: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020.
PRECISION BIOSCIENCES INC
Report date September 25, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,492 |
Reported balance
After 2026-09-25 transaction · row 1
1 source rowRow 1 · 2026-09-25 · Purchase · Acquired 2,609 · Balance 47,492 |
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-08 · Disposition to issuer · Disposed 5,455 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $55.04 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-08 · Disposition to issuer · Disposed 21,729 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock.
F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
MEDICINES CO /DE
Report date January 06, 2020 · Filed January 06, 2020
Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-06 transaction · row 1
1 source rowRow 1 · 2020-01-06 · Disposition to issuer · Disposed 7,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.90 | IndirectBy grantor retained annuity trust | 0 |
Reported balance
After 2020-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-06 · Disposition to issuer · Disposed 27,243 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.86 | IndirectBy grantor retained annuity trust | 0 |
Reported balance
After 2020-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-06 · Disposition to issuer · Disposed 9,141 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.81 | IndirectBy grantor retained annuity trust | 0 |
Reported balance
After 2020-01-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-06 · Disposition to issuer · Disposed 8,410 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price").
F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.
F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.
Sage Therapeutics, Inc.
Report date July 31, 2025 · Filed July 31, 2025
Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time").
F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2012 Filed Dec 4, 2012 00:27 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 62 | $25.02 | $1,551.24 |
DisclosureSEC source: 0001225208-12-024260 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,129 Underlying: Common Stock · 62 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2012 Filed Nov 19, 2012 13:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 119 | $23.66 | $2,815.54 |
DisclosureSEC source: 0001225208-12-023380 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,067 Underlying: Common Stock · 119 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2012 Filed Nov 1, 2012 22:04 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 69 | $24.87 | $1,716.03 |
DisclosureSEC source: 0001225208-12-022173 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,948 Underlying: Common Stock · 69 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2012 Filed Oct 16, 2012 21:42 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 63 | $25.57 | $1,610.91 |
DisclosureSEC source: 0001225208-12-021409 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,879 Underlying: Common Stock · 63 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 28, 2012 Filed Oct 1, 2012 22:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 66 | $24.85 | $1,640.10 |
DisclosureSEC source: 0001225208-12-020386 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,816 Underlying: Common Stock · 66 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 14, 2012 Filed Sep 18, 2012 12:17 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 71 | $23.80 | $1,689.80 |
DisclosureSEC source: 0001225208-12-019787 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Stock · 71 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2012 Filed Sep 4, 2012 23:12 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 71 | $23.86 | $1,694.06 |
DisclosureSEC source: 0001225208-12-018916 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,679 Underlying: Common Stock · 71 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2012 Filed Aug 16, 2012 23:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 114 | $24.04 | $2,740.56 |
DisclosureSEC source: 0001225208-12-018029 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,608 Underlying: Common Stock · 114 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2012 Filed Aug 1, 2012 22:29 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 66 | $24.04 | $1,586.64 |
DisclosureSEC source: 0001225208-12-017096 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,494 Underlying: Common Stock · 66 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 13, 2012 Filed Jul 17, 2012 13:19 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 73 | $22.81 | $1,665.13 |
DisclosureSEC source: 0001225208-12-016324 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,428 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 12:12 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 73 | $23.00 | $1,679.00 |
DisclosureSEC source: 0001225208-12-015282 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,355 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2012 Filed Jun 19, 2012 18:02 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 73 | $22.61 | $1,650.53 |
DisclosureSEC source: 0001225208-12-014560 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,282 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2012 Filed Jun 1, 2012 21:35 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 78 | $21.87 | $1,705.86 |
DisclosureSEC source: 0001225208-12-013542 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,209 Underlying: Common Stock · 78 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2012 Filed May 16, 2012 19:33 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 112 | $22.30 | $2,497.60 |
DisclosureSEC source: 0001225208-12-012565 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,131 Underlying: Common Stock · 112 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2012 Filed May 1, 2012 20:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 77 | $22.90 | $1,763.30 |
DisclosureSEC source: 0001225208-12-010660 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,019 Underlying: Common Stock · 77 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 13, 2012 Filed Apr 17, 2012 14:27 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 13 | $21.85 | $284.05 |
DisclosureSEC source: 0001225208-12-009864 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,942 Underlying: Common Stock · 13 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:44 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 144,033 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005632 · doc4.xml · derivative · entry 5 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,033 Underlying: Common Stock · 144,033 shares Expires 2019-02-23 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:44 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 169,903 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005632 · doc4.xml · derivative · entry 4 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,903 Underlying: Common Stock · 169,903 shares Expires 2017-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:44 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 32,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005632 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,517 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:36 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 135,397 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007681 · doc4.xml · derivative · entry 4 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,397 Underlying: Common Stock · 135,397 shares Expires 2018-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:36 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 163,551 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007681 · doc4.xml · derivative · entry 3 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,551 Underlying: Common Stock · 163,551 shares Expires 2016-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:36 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 37,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007681 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,130 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.